Document is current
Any future updates will be listed below
-
Authors
McQuade, Jennifer L. https://orcid.org/0000-0002-2393-2172
Homsi, Jade
Torres-Cabala, Carlos A.
Bassett, Roland
Popuri, Rashmi Murthy
James, Marihella L.
Vence, Luis M.
Hwu, Wen-Jen
-
Funding
Funding for this research was provided by:
National Institutes of Health (CA009666)
National Cancer Institute (P30 CA016672)
- License Information
-
More Information
Article History
Received: 10 August 2018
Accepted: 6 December 2018
First Online: 19 December 2018
Author’s information
: Not applicable
: The study protocol and all amendments were approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center (protocol #2010–0113). The study was conducted in accordance with the protocol and its amendments, Good Clinical Practice Guidelines, and the Declaration of Helsinki. All patients provided written informed consent.
: N/A
: W.-J. Hwu reports funding to the institution for clinical research from Bristol-Myers Squibb, MedImmune, and Merck & Co., Inc. and serving on an advisory board for Merck & Co., Inc.Jade Homsi reports speaking and consulting with Merck & Co., Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
